Antitumor necrosis factor (anti-TNF) therapy has proven efficacy in the induction and maintenance of remission in children with Crohn's disease (CD). With the increased use of these medications, several adverse events have been associated, including the emergence of neurologic side effects. While demyelinating conditions and neuropathy associated with anti-TNF therapy have been reported in adults, seizures have been anecdotally described in case reports. We describe a case of an adolescent boy who experienced an infliximab-associated seizure during an infusion and the potential role that medication antibody levels may have played in this adverse event.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191561PMC
http://dx.doi.org/10.1097/PG9.0000000000000101DOI Listing

Publication Analysis

Top Keywords

crohn's disease
8
adverse event
8
anti-tnf therapy
8
seizure infliximab
4
infliximab infusion
4
infusion child
4
child crohn's
4
disease illustration
4
illustration neurologic
4
neurologic adverse
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!